Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

被引：4

作者：

Chaganti, Sridhar ^{[1
]}

Maycock, Shanna ^{[2
]}

McIlroy, Graham ^{[2
]}

Iqbal, Waleed A. ^{[2
]}

Mason, John ^{[3
]}

Kanfer, Edward ^{[4
]}

Kassam, Shireen ^{[5
]}

Cwynarski, Kate ^{[6
]}

Wrench, David ^{[7
]}

Arumainathan, Arvind K. ^{[8
]}

Fox, Christopher P. ^{[9
]}

Johnson, Rod ^{[10
]}

McKay, Pam ^{[11
]}

Paneesha, Shankara ^{[12
]}

Rowntree, Clare J. ^{[13
]}

Balotis, Constantine-George ^{[14
]}

Collins, Graham P. ^{[15
]}

Davies, Andrew ^{[16
]}

Wright, Josh

Wheatley, Keith ^{[3
]}

Menne, Tobias F.

机构：

[1] Univ Hosp Birmingham NHS Fdn Trust, Ctr Clin Haematol, Birmingham, England

[2] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, England

[3] Univ Birmingham, Canc Res UK Clin Trials Unit CRCTU, Birmingham, England

[4] Hammersmith Hosp, London, England

[5] Kings Coll Hosp London, London, England

[6] Univ Coll London Hosp, Dept Haematol, London, England

[7] Guys Hosp, Guys & St Thomas NHS Fdn Trust, London, England

[8] Clatterbridge Canc Ctr, Liverpool, Merseyside, England

[9] Nottingham Univ Hosp NHS Trust, Nottingham, England

[10] St Jamess Hosp Leeds, Leeds, W Yorkshire, England

[11] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[12] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England

[13] Univ Wales Hosp, Dept Haematol, Cardiff, Wales

[14] Leicester Royal Infirm, Leicester, England

[15] Oxford Univ Hosp NHS Fdn Trust, Oxford, England

[16] Univ Southampton, NCRI Canc Res UK Expt Canc Medicines Ctr, Fac Med, Southampton, England

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146494

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2492

引用

页数：8

共 13 条

[1] Real-world outcomes of post-transplant lymphoproliferative disorder treated with risk-stratified sequential therapy
DeStefano, Christin B.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : 398 - 399
[2] Ibrutinib as part of risk-stratified fi ed treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial
Chaganti, Sridhar
Maycock, Shanna
Mcilroy, Graham
Jackson, Aimee
Bishop, Rebecca
Johnson, Sarah
Kanfer, Edward
Kassam, Shireen
Cwynarski, Kate
Wrench, David
Arumainathan, Arvind
Fox, Christopher P.
Johnson, Rod
Mckay, Pam
Paneesha, Shankara
Rowntree, Clare
Balotis, Constantine
Collins, Graham P.
Davies, Andrew
Wright, Josh
Burns, Sarah
Laurence, Arian
Wheatley, Keith
Menne, Tobias
BLOOD, 2024, 144 (04) : 392 - 401
[3] Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST).
Trappe, Ralf Ulrich
Dierickx, Daan
Reinke, Petra
Neuhaus, Ruth
Morschhauser, Franck
Zaucha, Jan M.
Mollee, Peter
Zimmermann, Heiner
Dreyling, Martin H.
Duehrsen, Ulrich
Verhoef, Gregor E. G.
Lehmkuhl, Hans
Subklewe, Marion
Huettmann, Andreas
Tousseyn, Thomas
Tarella, Corrado
Leblond, Veronique
Anagnostopoulos, Ioannis
Riess, Hanno
Choquet, Sylvain
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[4] Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
Zimmermann, Heiner
Koenecke, Christian
Dreyling, Martin H.
Pott, Christiane
Duehrsen, Ulrich
Hahn, Dennis
Meidenbauer, Norbert
Hauser, Ingeborg A.
Rummel, Mathias J.
Wolf, Dominik
Heuser, Michael
Schmidt, Christian
Schlattmann, Peter
Ritgen, Matthias
Siebert, Reiner
Oschlies, Ilske
Anagnostopoulos, Ioannis
Trappe, Ralf U.
LEUKEMIA, 2022, 36 (10) : 2468 - 2478
[5] Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
Heiner Zimmermann
Christian Koenecke
Martin H. Dreyling
Christiane Pott
Ulrich Dührsen
Dennis Hahn
Norbert Meidenbauer
Ingeborg A. Hauser
Mathias J. Rummel
Dominik Wolf
Michael Heuser
Christian Schmidt
Peter Schlattmann
Matthias Ritgen
Reiner Siebert
Ilske Oschlies
Ioannis Anagnostopoulos
Ralf U. Trappe
Leukemia, 2022, 36 : 2468 - 2478
[6] Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial
Zimmermann, Heiner
Koenecke, Christian
Dreyling, Martin H.
Pott, Christiane
Duhrsen, Ulrich
Hahn, Dennis
Meidenbauer, Norbert
Hauser, Ingeborg A.
Rummel, Mathias J.
Wolf, Dominik
Heuser, Michael
Schmidt, Christian
Schlattmann, Peter
Ritgen, Matthias
Siebert, Reiner
Oschlies, Ilske
Anagnostopoulos, Ioannis
Trappe, Ralf Ulrich
BLOOD, 2021, 138
[7] Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Trappe, Ralf
Oertel, Stephan
Leblond, Veronique
Mollee, Peter
Sender, Monica
Reinke, Petra
Neuhaus, Ruth
Lehmkuhl, Hans
Horst, Heinz August
Salles, Gilles
Morschhauser, Franck
Jaccard, Arnaud
Lamy, Thierry
Leithaeuser, Malte
Zimmermann, Heiner
Anagnostopoulos, Ioannis
Raphael, Martine
Riess, Hanno
Choquet, Sylvain
LANCET ONCOLOGY, 2012, 13 (02): : 196 - 206
[8] Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial
Trappe, Ralf
Oertel, Stephan H. K.
Leblond, Veronique
Mollee, Peter
Sender, Monica
Reinke, Petra
Neuhaus, Ruth
Lehmkuhl, Hans
Horst, Heinz A.
Salles, Gilles Andre
Morschhauser, Franck
Jaccard, Arnaud
Lamy, Thierry
Leithaeuser, Malte
Anagnostopoulos, Ioannis
Raphael, Martine
Riess, Hanno
Choquet, Sylvain
BLOOD, 2011, 118 (21) : 401 - 402
[9] Successful Treatment of Rituximab-Resistant Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disorder Using R-CHOP
Kuriyama, Takuro
Kawano, Noriaki
Yamashita, Kiyoshi
Ueda, Akira
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2014, 54 (02) : 149 - 153
[10] Sequential treatment with the anti-CD 20 antibody rituximab and CHOP plus GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): First interim analysis of a multicenter phase II study
Trappe, R
Oertel, S
Choquet, S
LeBlond, V
Papp-Vary, M
Riess, H
BLOOD, 2005, 106 (11) : 274A - 274A

← 1 2 →